Related Experiment Video
Updated: Aug 14, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Developing a core outcome set (COS) for Dementia with Lewy bodies (DLB)
Emilia Grycuk1, Emily Eichenholtz2, Dag Aarsland3
1Department of Psychiatry, School of Medicine, Trinity College Dublin, Ireland.
A core outcome set (COS) for Dementia with Lewy bodies (DLB) is being developed to standardize research. This ensures comparable, relevant outcomes for better treatment decisions in DLB clinical trials.
Area of Science:
- Neurology
- Gerontology
- Clinical Research Methodology
Background:
- Dementia with Lewy bodies (DLB) presents diverse symptoms (motor, neuropsychiatric, autonomic).
- DLB research is limited compared to Alzheimer's disease, with varied outcome measures hindering progress.
- A standardized Core Outcome Set (COS) is crucial for comparable and actionable DLB research.
Purpose of the Study:
- To develop a standardized Core Outcome Set (COS) for Dementia with Lewy bodies (DLB).
- To ensure consistent and relevant outcome measures in DLB treatment trials.
- To facilitate global comparison and implementation of DLB research findings.
Main Methods:
- Systematic review (PRISMA guidelines) for initial outcome identification.
- Multi-stage Delphi process involving diverse stakeholders (clinicians, patients, policymakers).
- Consensus meetings to finalize outcomes and select measurement instruments.
Main Results:
- The project aims to establish a definitive DLB-COS.
- Identification of appropriate instruments for measuring DLB-COS outcomes is a key objective.
- Global dissemination of the DLB-COS and associated instruments is planned.
Conclusions:
- The developed DLB-COS will standardize outcome selection in treatment trials.
- This initiative will enhance the comparability and utility of DLB research worldwide.
- The project addresses a critical need for consistent methodology in DLB research and clinical practice.
More Related Videos
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
06:16Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
Published on: June 6, 2020
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....
Parkinson's Disease: Overview
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...